Kornimate/medical-research-clean huggingface dataset:
tubeless percutaneous nephrolithotomy without reverse insertion of a ureteral catheter

Conditions: Urinary Calculi; Percutaneous Nephrolithotomy

Summary: percutaneous nephrolithotomy(pcnl) is a surgical method for upper urinary calculi. the advent of tubeless pcnl (without indwelling nephrostomy tube) has been proved to be safe and effective in reducing postoperative discomfort, shortening hospitalization time and reducing hospitalization costs. traditional tubeless pcnl usually involves retrograde insertion of the ureteral catheter, which may cause many ureteral related surgical complications. however, there are few reports on tubeless pcnl without reverse ureteral catheter insertion. the goal of this study is to explore the safety and effectiveness of the tubeless pcnl without reverse ureteral catheter insertion.

this is a key clinical research project of the university of south china (no. usckf201902k01). the goal of this study is to comparative the safety and clinical efficacy between the tubeless percutaneous nephrolithotomy without reverse insertion of a ureteral catheter and the traditional tubeless percutaneous nephrolithotomy with reverse insertion of a ureteral catheter in the treatment of upper urinary calculi, and to explore the former' applications. it is a prospective, randomized controlled single center study that is conducted for 2 years anticipatively. the clinic physician is responsible for patient recruitment and allocation and the application of computerized random-number generation. for random allocation, participants are given random numbers. participants with odd numbers are assigned to experimental group, where they undergo tubeless pcnl without reverse insertion of a ureteral catheter. participants with even numbers are assigned to control group and undergo tubeless pcnl with reverse insertion of a ureteral catheter. the doctors managing the operations accept participants and execute the surgical treatments. all participants sign clinical-trial informed consent and surgical informed consent during the preoperative conversation. follow-up observation is conducted for 1 month after surgery. after completion of the study, we collect relevant clinical data from the participants. the primary and secondary outcomes are analyzed and compared between the two groups.

Eligibility criteria:
inclusion criteria: * participants who met the the applications of pcnl surgery in the 2019 chinese guidelines for the diagnosis and treatment of urological diseases * participants who agree to undergo tubeless pcnl * the participants' maximum diameter of the stone should be less than 3.5cm exclusion criteria: * confirmation by computerized tomography (ct) images and blood biochemical indicators of infectious stones or complex staghorn stones * obvious surgical contraindications, such as severe heart and lung insufficiency, abnormal coagulatory function * previous pcnl or nephrolithotomy, presence of an indwelling ureteral stent or nephrostomy tube before surgery * renal trauma or congenital malformation of the urinary system

Keywords: ureteral catheter without reverse insertion percutaneous nephrolithotomy tubeless urinary calculi
finding the latent treponema pallidum

Conditions: Syphilis

Summary: some syphilitic patients remain in a serologically positive state after the recommended therapy. whether a serofast state could represent a persistent low-level infection by treponema pallidum is still unknown. the possibility that persistent nontreponemal antibodies after treatment represent persistence of treponema pallidum was raised by some investigators. the investigators use the next-generation sequencing to test blood plasma, srum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

some syphilitic patients remain in a serologically positive state after the recommended therapy. whether a serofast state could represent a persistent low-level infection by treponema pallidum is still unknown. the possibility that persistent nontreponemal antibodies after treatment represent persistence of treponema pallidum was raised by some investigators. the investigators use the next-generation sequencing to test blood plasma, serum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.

Eligibility criteria:
inclusion criteria: * all clinical diagnosis of syphilis cases exclusion criteria: * auto-immune disease (such as sle) * lyme disease

Keywords: syphilis serofast
food intake and gut hormones in patients who have undergone upper gastrointestinal surgery for cancer

Conditions: Esophageal Neoplasms; Stomach Neoplasms; Weight Loss; Malnutrition

Summary: improvements to treatment strategies for patients upper gastrointestinal cancers have produced an increasing population of people who remain free from disease recurrence in the long term. weight loss and nutritional problems are common among patients who attain long-term remission and cure after surgery for upper gastrointestinal cancers. however, the mechanisms underlying these problems are not well understood. in this study the investigators aim to determine whether reduced food intake after upper gastrointestinal surgery is caused by early satiety related to exaggerated post-prandial gut hormone responses. this is a randomized, double-blind, placebo controlled, crossover study of the effect of 100μg octreotide sc on ad libitum food intake in patients free from complications or recurrence at least one year post-oesophagectomy, gastrectomy or pancreaticoduodenectomy. a comparator group of age, weight and gender matched subjects will be studied concurrently, and caloric intake and subjective symptom scores after administration of octreotide versus placebo among surgical and comparator subjects will be assessed.


Eligibility criteria:
inclusion criteria: 1. surgical procedure: two-stage, three-stage or transhiatal oesophagectomy with gastric conduit reconstruction and pyloroplasty, total gastrectomy with roux-en-y reconstruction, pancreaticodueodenectomy, or matched unoperated healthy controls 2. at least one year in remission post-resection (surgical groups) exclusion criteria: 1. pregnancy, breastfeeding 2. significant and persistent chemoradiotherapy and/or surgical complication 3. other previous upper gastrointestinal surgery 4. significant dysphagia or odynophagia, unable to eat 5. other disease or medications which may affect satiety gut hormone responses 6. active and significant psychiatric illness including substance misuse 7. cognitive or communication issues or any factors affecting capacity to consent to participation 8. history of significant food allergy, certain dietary restrictions 9. confirmed or suspected residual or recurrent disease after surgery, second primary malignancy 10. other reconstruction (eg colonic or jejunal interposition) 11. any contraindication to octreotide administration

Keywords: glucagon-like peptide 1 peptide yy ghrelin satiety response appetite hunger somatostatin octreotide anastomosis, roux-en-y digestive system surgical procedures pharmacologic actions physiological effects of drugs endocrine system diseases enteroendocrine cells gastrointestinal agents
a trial of transcutaneous nerve stimulation for oab

Conditions: Overactive Bladder

Summary: overactive bladder causes urinary frequency, urgency and in some cases urgency incontinence. this study is testing the efficacy of transcutaneous tibial nerve stimulation (using skin patch electrodes via a transcutaneous electrical nerve stimulation (tens) machine) for the treatment of women with clinical symptoms of overactive bladder.


Eligibility criteria:
inclusion criteria: 1. female, \>18 years of age, with the clinical diagnosis of overactive bladder. 2. failure of behavioral measures and pharmacologic therapy to adequately control overactive bladder symptoms. 3. baseline patient perception of bladder condition score of 2 or higher. exclusion criteria: 1. current or previous percutaneous or sacral neuromodulation therapy 2. stress predominant urinary incontinence 3. newly added bladder medication or dose change with the last 2 months (tamsulosin, silodosin, alfuzosin, terazosin, baclofen, diazepam, amitriptyline, imipramine, ddavp, tolterodine, oxybutynin, fesoterodine, darifenacin, solifenacin, trospium, mirabegron) 4. intravesical botulinum toxin use within the last 1 year 5. implanted pacemaker or defibrillator 6. history of epilepsy 7. unable or unwilling to commit to study treatment schedule 8. pregnant, or possible pregnancy planned for the duration of the study period 9. active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma) 10. documented allergy to patch electrodes or their adhesive 11. abnormal sensory function of the lower limb 12. metallic implant within the lower limb
novel desensitization kidney transplantation

Conditions: Kidney Transplantation; End Stage Kidney Disease (ESRD)

Summary: this proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly hla sensitized kidney transplant candidates.

this is a pilot study to test the safety and effectiveness of the desensitization therapy with belatacept and proteasome inhibitor to increase the likelihood of of finding an acceptable donor for highly hla sensitized kidney transplant candidates.

Eligibility criteria:
inclusion criteria: * highly sensitized patient cpra 99-100% and actively listed for kidney transplantation at the kidney transplantation program at university fo chicago * ebstein barr virus (ebv) immunoglobulins (igg) seropositive * no active systemic infection * no allergy to proteasome inhibitors (bortezomib), or to belatacept * no known malignancy in the previous 2 years except for non-melanomatous skin cancer * female who agrees to practice 2 effective methods of contraception through 3 months after the last dose of bortezomib * patient vaccinated against hepatitis b virus with positive level of hbsab * patients fully vaccinated against coronavirus disease 2019 at least 2 weeks prior to the start of the 1st cycle. * actively listed for kidney transplant at the transplant institute at university of chicago exclusion criteria: * patient with significant neuropathy by the common terminology criteria for adverse events (ctcae) criteria within 14 days before enrollment (grades 3-4 or grade 2 with pain) * myocardial infarction within 6 months of enrollment or has heart failure in acute dialysis quality initiative (adqi) esrd classification system class 2 non restrictive (2nr) or greater, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ecg evidence of acute ischemia or active conduction system abnormalities * patient who received other investigational drugs within 14 days prior to initiation of study treatment * receipt of a live vaccine within 4 weeks prior to initiation of study treatment * evidence of severe liver disease by history or physical exam or with abnormal liver profile ( \> 1.5 times upper limit of normal within 30 days of consent) * female who is breast feeding or pregnant * untreated latent tuberculosis * history of post transplant lymphoproliferative disease (ptld) * patient still carrying previous kidney transplant.

Keywords: kidney transplantation sensitized patients belatacept proteasome inhibitor
effect of vitamin d supplementation on erythropoietin dosage in hemodialysis patients who have vitamin d deficiency

Conditions: Vitamin D Deficiency; Anemia

Summary: while vitamin d supplementation is safe and effective in repleting vitamin d levels in dialysis patients, the impact on anemia is unknown. the majority of hemodialysis patients require erythropoietin supplementation to maintain their serum hemoglobin between 11 and 12 gm/dl, a drug that is both costly and associated with significant side effects. if repletion of vitamin d significantly decreases erythropoietin requirements in hemodialysis patients, it would result in a substantial reduction in patient care costs. our aim is to study the impact of ergocalciferol supplementation in hemodialysis patients with 25-hydroxyvitamin d deficiency. the investigators anticipate approximately 30% reduction in erythropoietin dose requirement in our hemodialysis population.


Eligibility criteria:
inclusion criteria: * all hemodialysis patients at the kaiser permanente los angeles medical center with vitamin d deficiency \[defined by 25-hydroxyvitamin d level less than 30 ng/ml\] exclusion criteria: * non-renal causes of anemia (myelodysplastic syndrome, multiple myeloma, pure red cell aplasia, thallassemia, and sickle cell anemia) * active cancer * aids * refused erythropoeitin, intravenous iron or vitamin d analogs in the past * no erythropoeitin requirement for greater than 6 weeks
preventing depression in the children of depressed african american mothers

Conditions: Depression

Summary: the purpose of the study is to adapt and test the preventive intervention project for urban african american mothers with depression and their children.

abstract background: there is limited representation of ethnic minorities in preventive interventions for the generational impact of maternal depression. methods: the preventive intervention project (pip) was adapted to be culturally and contextually relevant for urban african american mothers with depression and their children. a pilot clinical trial (pip vs. lecture) was conducted.

Eligibility criteria:
mothers: inclusion criteria: * african american * primary current or past-year diagnostic and statistical manual (dsm-iv) diagnosis of major depressive disorder, dysthymic disorder, or depressive disorder not otherwise specified * parent or guardian and primary caregiver of a child 8 to 14 years old * resided at least part time for the past year with the targeted child * may be receiving psychopharmacological treatment, psychosocial services, or both exclusion criteria: * current or lifetime history of schizophrenia * current or lifetime history of bipolar disorder * current or past-year diagnosis of alcohol or drug dependency * serious medical disorder, neurological disorder, condition, or chronic pain that prevents participation * documented mental retardation * current suicide risk sufficient to preclude outpatient treatment children: inclusion criteria: * have an african american mother with a depressive disorder * 8 to 14 years old * reside at least part time with mother exclusion criteria: * currently in treatment for depression or an anxiety disorder * presence of a medical or psychiatric condition contraindicating study intervention, such as mental retardation, suicidality, or pervasive developmental disorder

Keywords: african american mothers children african american families parental depression preventive intervention
is ultrasound-guided foam sclerotherapy a cost-effective alternate for treatment of varicose veins?

Conditions: Pain; Leg Edema; Cost Effectiveness; Cosmesis

Summary: . it is the aim of this paper is to discuss our experience of foam sclerotherapy for varicose veins atour hospital

we will manage all patients with vericose veins with injection sclerotherapy and will monitor there response in terms of relive in vsisble veins, swelling and pain. we also want to evaluate hoe many sessions of injection sclerotherapy are required for complete resolution of symptoms.

Eligibility criteria:
inclusion criteria: * all the patients who present with symptomatic varicose veins underwent a duplex scan by radiologist to identify site of reflux and condition of deep veins. if the patient is a candidate for intervention then he is offered surgery or foam sclerotherapy exclusion criteria: * recurrent and secondary varicose veins
cognitive behavioral therapy for obesity

Conditions: Obesity

Summary: the purpose of this pilot study is to assess patient accessibility, interest and response in order to design an adequately powered study to compare brief, group cognitive behavioral therapy (cbt) for weight loss to usual care in non-demented patients above the age of 18 years old who are currently taking atypical antipsychotic medications. this pilot study is necessary, with current limitations of data in this area, to design an adequately powered study to address the difficulties managing metabolic syndrome risk factors in patients on antipsychotics.


Eligibility criteria:
inclusion criteria: 1. age 18 years and above 2. patients with diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder determined by assessment with chart review, currently taking at least one atypical antipsychotic, started at least 2 months prior to randomization 3. body mass index (bmi) greater than 30 4. ability to consent to treatment, determined by the patient's treating/referring physician exclusion criteria: 1. patients with premorbid medical problems that preclude involvement in a weight loss program 2. active substance abuse or dependence, indicated by a positive urine drug screen in the last 3 months 3. mini- mental status exam (mmse) less than 24 4. active psychosis or mania, determined by administration of the panss score greater than 3 on the following items; delusions, conceptual disorganization, hallucinatory behavior, blunted affect, social withdrawal, lack of spontaneity and conversation flow, mannerisms and posturing, and unusual thought content, and ymrs greater than 10, respectively 5. active major depressive episode, determined by administration of ham-d greater than 13 6. patients taking any medications for weight loss or currently enrolled in a weight loss program 7. changes in medication regimen for diabetes or dyslipidemia within the last 3 months

Keywords: obesity cbt atypical antipsychotics metabolic syndrome
motivational interviewing compared to psychoeducation for smoking precontemplators with smi

Conditions: Nicotine Dependence

Summary: the investigators primary hypothesis was that recipients of the motivational interviewing intervention would be significantly more likely than those assigned to the psychoeducation intervention to demonstrate increased readiness to quit smoking at the end of the intervention and to seek smoking cessation treatment in the one month period following the intervention. we also predicted that the psychoeducation intervention would result in greater improvements in smoking knowledge.


Eligibility criteria:
inclusion criteria: * 18-65 years of age * had a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or chronic major depressive disorder by diagnostic and statistical manual of mental disorders, fourth edition criteria * smoked at least 10 cigarettes per day * at baseline, reported not being ready to quit smoking within the next 30 days (i.e., in precontemplation or contemplation stages). exclusion criteria: -

Keywords: transtheoretical model stages of change nicotine dependence severe mental illness
optical spectroscopy in evaluating tumor margins in patients who have undergone surgery for breast tumors

Conditions: Breast Cancer

Summary: rationale: diagnostic procedures, such as optical spectroscopy, may help learn the extent of disease and allow doctors to plan better treatment. purpose: this phase i trial is studying optical spectroscopy to see how well it works in evaluating tumor margins in patients who have undergone surgery for breast cancer.

objectives: * to develop a non-invasive detection tool that evaluates breast tumor margins in real-time to guide tumor resection during partial mastectomy procedures. * to conduct an ex vivo optical spectroscopic study in operating rooms on breast tissue samples obtained immediately following resection to assess the efficacy of using this tool in differentiating breast tumor or tumor margins from normal breast tissue. outline: breast tissue samples obtained immediately following resection are examined in the operating room using optical spectroscopy to evaluate the margin tissue. during spectroscopy, all lights, except for the surgical lights, are turned off and the lateral, superior, medial, inferior, deep, and anterior margins of the breast tissue sample are examined using a fiber-optic probe, a nitrogen laser, and a broad band white light source. reflectance and fluorescence spectra are measured at each of these margins by a system operator. the measured margins are then immediately marked by sutures placed by the surgeon. additional margins may be measured at the surgeon's and system operator's discretion. the breast tissue sample is then delivered to surgical pathology, where shave biopsies are performed at the suture-marked sites to provide a direct correlation between spectroscopy measurements and tissue pathology. data collected in this study, including spectral data, gross diagnosis of the patient's tumor, and histological identities of all specimens collected, will be kept in the research record for at least 6 years after the study is finished.

Eligibility criteria:
disease characteristics: * scheduled to undergo lumpectomy, partial or radical mastectomy, or excisional biopsy for breast tumor at vanderbilt university hospital * hormone receptor status not specified patient characteristics: * male or female * menopausal status not specified * not pregnant prior concurrent therapy: * see disease characteristics inclusion criteria only adult patients between the ages of 18-99 years with breast tumor undergoing lumpectomy, radical mastectomy or excisional biopsy procedure will be considered exclusion criteria pregnant women will be excluded from the participation.

Keywords: male breast cancer stage ia breast cancer stage ib breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer
parathyroid hyperplasia in patients with chronic kidney disease.

Conditions: Chronic Kidney Diseases

Summary: secondary hyperparathyroidism is an important complication in patient with chronic kidney disease . it is associated with bone complication and an increase in cardiovascular mortality the parathyroid hormone rises in these patients as consequence of low concentration of vitamin d3 ,reduction in quantities of serum calcium, phosphorus retention and reduction of vitamin d receptors sensitive to calcium.


Eligibility criteria:
inclusion criteria: * stage 5 chronic renal failure * dialysis (peritoneal ,or hemodialysis) since 3---5 years exclusion criteria: * previous of neck surgery. * patients refusal to participate in the study or voluntary withdrawal
injectable collagen scaffold™ combined with mscs transplantation for brain injury

Conditions: Brain Injury

Summary: the purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with mesenchymal stem cells (mscs) transplantation in patients with brain injury.


Eligibility criteria:
inclusion criteria: 1. male or female，35-75 years old. 2. the surgery time should be \> 6 hours after symptom onset. 3. glasgow coma score (gcs) was 9-15. 4. ct diagnosis of intracerebral hemorrhage (25-40 ml), except for patients with signs of craniotomy to remove the hematoma. 5. signed informed consent obtained from the patient or patient's legally authorized representative. exclusion criteria: 1. glasgow coma scale of \<8. 2. patients suffering severe heart failure, severe lung disease, uremia, cirrhosis, end-stage cancer, coagulation disorders, stroke sequela. 3. asphyxia, cardiac arrest or successful cardiopulmonary resuscitation before hospitalization. 4. lactating or pregnant woman. 5. refuse to sign informed content.